CTOs on the Move

Seasons

www.seasons.org

 
Seasons Hospice & Palliative Care (SHPC) is a community-based organization with an ongoing mission to find creative solutions that add quality to end-of-life care. The caregivers at SHPC hold steadfast to the patient/family focus of hospice care. We recognize that individuals and families are the experts in their own care, and we continuously strive for excellence beyond accepted standards. We are born into a world of comfort, warmth and love, and it our belief that we should all leave this world in the same way. To further that goal, we work with communities to increase the awareness of hospice as ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million
  • www.seasons.org
  • 6400 Shafer Court Suite 700
    Rosemont, IL USA 60018
  • Phone: 847.692.1000

Executives

Name Title Contact Details

Similar Companies

BIOMET 3i

BIOMET 3i is a Palm Beach Gardens, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Co-Bio Consulting

Co-Bio Consulting is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

S. TX Emergency Care Foundation

S. TX Emergency Care Foundation is a Harlingen, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CompManagement Health Systems

CompManagement Health Systems, Inc. is a Dublin, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.